The effect of magnesium supplementation in improving depressive symptoms in patients with major depressive disorder treated with antidepressants

Phase 3

• Conditions: Major Depressive Disorder.; Major depressive disorder, single episode, severe with psychotic features; F32.3

• Registration Number: IRCT20200823048493N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Patients with major depression based on DSM-S and according to the diagnosis of a psychiatrist
Age over 18 years
Having minimum education to read the questionnaire

Exclusion Criteria

Neurological disorders
Taking alcohol and drug use during the last 6 months
Active suicidal thoughts
Pregnancy and lactation
Mental retardation
Liver and kidney failure
Receiving monooxidase inhibitors during the last 8 weeks
History of seizures
Taking magnesium-interfering drugs
Presence of uncontrolled diseases such as diabetes and high blood pressure
Allergy to antidepressants or magnesium supplements

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression. Timepoint: In weeks 0, 2, 4 6. Method of measurement: Via Beck Depression Inventory.

Secondary Outcome Measures

Name	Time	Method
Side effects such as diarrhea. Timepoint: 6 weeks after intervention. Method of measurement: Through questions from the patient.